Search results
Here’s what a Nobel Prize-winning scientist wants you to know about the Covid-19 vaccines and the...
CNN via Yahoo News· 4 hours agoIn his new book “The Catalyst,” Thomas R. Cech talks about the Covid-19 vaccines, what RNA means for...
US scientists create world’s first seedless blackberry using CRISPR
Interesting Engineering· 6 hours agoThis has led them to develop the world’s first seedless blackberry. Short for Clustered Regularly...
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
Motley Fool via Yahoo Finance· 1 day agoCathie Wood is buying the dip on two biotechs in particular, so for her, the answer to that question...
In Central Florida, scientists battle citrus disease with genetic engineering
WUSF 89.7· 7 hours agoOne March morning, more than eighty years after his family first started growing oranges in DeLeon...
Cathie Wood's ARK buys PagerDuty, CRISPR, sells Zoom stock By Investing.com
Investing.com· 5 days agoCathie Wood's ARK buys PagerDuty, CRISPR, sells Zoom stock
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential...
Morningstar· 7 days agoRecursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a ...
CRISPR Therapeutics AG [NASDAQ: CRSP] Sees Decrease in Stock Value – Knox Daily
Knox Daily· 6 days agoThe buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $1,173,232 ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 6 days agoBERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today ...
Evercore ISI cuts Editas Medicine stock target By Investing.com
Investing.com· 6 days agoThe firm's analyst has reduced the price target for the company's shares to $7.00 from the previous...
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial - Boston...
The Business Journals· 3 days agoOn Sunday, Intellia Therapeutics (Nasdaq: NTLA) said that its experimental gene-editing treatment...